Nearly every peptide drug guide on this site describes a compound as an "agonist" or "antagonist" of some specific receptor. Those three words, receptor, agonist, antagonist, are the basic vocabulary of how peptide drugs actually work, and they're worth understanding on their own rather than treating as technical noise.

What a Receptor Is

A receptor is a protein, usually sitting on or embedded in a cell's surface, shaped to recognize and bind a specific molecule, like a lock built for a particular key. When the right molecule binds to a receptor, it triggers a specific chain of events inside the cell, changes in gene activity, enzyme function, ion flow, or hormone release, depending on the receptor and cell type involved. The body's own hormones and neurotransmitters are the receptors' natural "keys"; peptide drugs work by being engineered to interact with those same locks, sometimes more precisely or durably than the natural molecule does.

What an Agonist Does

An agonist is a molecule that binds to a receptor and activates it, essentially mimicking the natural signal that receptor normally responds to, producing the same general type of effect the body's own hormone would. Semaglutide and tirzepatide, discussed throughout this site's guides, are GLP-1 receptor agonists: they bind to and activate the GLP-1 receptor, mimicking the body's natural GLP-1 hormone, which is why they produce effects like increased insulin release and reduced appetite. Growth-hormone-releasing peptides like sermorelin and CJC-1295 are agonists at a different receptor, the growth-hormone-releasing hormone receptor. "Agonist" doesn't mean a drug is safe or effective, only that it's acting in the same direction as the body's natural signal.

What an Antagonist Does

An antagonist does roughly the opposite: it binds to a receptor but blocks it rather than activating it, preventing the body's natural molecule, or another drug, from binding and producing its usual effect. This site's guide to degarelix describes an FDA-approved GnRH receptor antagonist, a drug that suppresses reproductive hormone signaling by directly blocking the GnRH receptor, in contrast to GnRH agonists like leuprolide, which initially stimulate the same receptor before ultimately causing it to down-regulate and produce a similar long-term suppressive effect. The practical result, lowering a specific hormone's downstream activity, can look similar from the outside even though agonists and antagonists get there through different mechanisms.

Why the Distinction Matters for Reading Drug News

When a new peptide compound is described as a "dual agonist" or "triple agonist," as with tirzepatide (GLP-1/GIP dual agonist) or retatrutide (GLP-1/GIP/glucagon triple agonist), that's describing how many different receptors the molecule activates at once, not a measure of strength or safety by itself. More receptors activated isn't automatically "better"; it changes which combination of downstream effects, and side effects, the drug is likely to produce, which is exactly why each new multi-receptor compound still has to go through its own clinical trials rather than being assumed safe or effective based on its mechanism alone.

The Bottom Line

Agonist and antagonist describe the direction a drug pushes a specific biological switch, on or off, not how well or safely it does so. Knowing which receptor a given peptide targets, and whether it's activating or blocking it, is the starting point for understanding what a drug is actually claimed to do, separate from the clinical evidence about whether it does so safely and effectively in humans.